Skip to main content
SpringerLink
Log in
SpringerLink
Log in

New Agents on the Horizon

  • Chapter
Current and Future Immunosuppressive Therapies Following Transplantation

  • 160 Accesses

Abstract

Today, many new small and large molecular weight molecules are being developed for use as immunosuppressive agents. As the understanding of mechanisms of immune function improves, immunosuppressive drug discovery and development is able to more specifically target activation pathways that predominate in immune rather than nonimmune cells, thus decreasing nonspecific toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S, Cho YW, Yuge J. Risk rate and long-term kidney transplant survival. Los Angeles: UCLA Tissue Typing Laboratory; 1997.

    Google Scholar 

  2. Vella JP, Sayegh MH. Maintenance pharmacological immunosuppressive strategies in renal transplantation. Postgrad Med J 1997;73(861):386–390.

    Article  PubMed  CAS  Google Scholar 

  3. Vella JP, O’Neill D, Atkins N, Donohoe JF, Walshe JJ. Sensitization to human leukocyte antigen before and after the introduction of erythropoietin. Nephrol Dial Transplant 1998; 13(8):2027–2032.

    Article  PubMed  CAS  Google Scholar 

  4. Novick AC, Ho-Hsieh H, Steinmuller DS, et al. Detrimental effect of cyclosporine on initial function of cadaver renal allografts following extended preservation: results of randomized prospective trial. Transplantation 1986;42:154.

    Article  PubMed  CAS  Google Scholar 

  5. Kahan BD. Drug Therapy: Cyclosporine. N Engl J Med 1989;321(25): 1725–1738.

    Article  PubMed  CAS  Google Scholar 

  6. Matas AJ, Gillingham KJ, Payne WD, Najarian JS. The impact of an acute rejection episode on long-term renal allograft survival (tl/2). Transplantation 1994;57(6):857–859.

    Article  PubMed  CAS  Google Scholar 

  7. Basadonna GP, Matas AJ, Gillingham KJ, Payne WD, Dunn DL, Sutherland DE, et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993;55(5):993–995.

    Article  PubMed  CAS  Google Scholar 

  8. Zhou YC, Cecka JM. Sensitization in renal transplantation. Clin Transpl 1991;1991:313–323.

    Google Scholar 

  9. Katznelson S, Cecka JM. Immunosuppressive regimens and their effects on renal allograft outcome. Clin Transpl 1996:361–371.

    Google Scholar 

  10. Katznelson S, Gjertson DW, Cecka JM. The effect of race and ethnicity on kidney allograft outcome. Clin Transpl 1995;1995(379):379–394.

    Google Scholar 

  11. Neylan JF. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1997;64(9): 1277–1282.

    Article  PubMed  Google Scholar 

  12. Neylan JF. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. FK506 Kidney Transplant Study Group. Transplantation 1998;65(4): 515–523.

    Article  PubMed  CAS  Google Scholar 

  13. Tejani A, Sullivan EK. Factors that impact on the outcome of second renal transplants in children. Transplantation 1996;62(5):606–611.

    Article  PubMed  CAS  Google Scholar 

  14. Gjertson DW. Multifactorial analysis of renal transplants reported to the United Network for Organ Sharing Registry: a 1994 update. Clin Transpl 1994:519–539.

    Google Scholar 

  15. Cecka JM. The UNOS Scientific Renal Transplant Registry-ten years of kidney transplants. Clin Transpl 1997:1–14.

    Google Scholar 

  16. Thorogood J, Houwelingen JC, Persijn GG, Zantvoort FA, Schreuder GM, van RJ. Prognostic indices to predict survival of first and second renal allografts. Transplantation 1991; 52(5):831–836.

    Article  PubMed  CAS  Google Scholar 

  17. Zandvoort FA, D’Amaro J, Persijn GG, Cohen B, Schreuder GM, van Rood JJ, et al. The impact of HLA-A matching on long-term survival of renal allografts. Transplantation 1996;61(5):841–844.

    Article  Google Scholar 

  18. Mytilineous J, Lempert M, Middleton D, Williams F, Cullen C, Scherer S, et al. HLA class I of 215 “HLA-A,-B,-DR zero mismatched” kidney transplants. Tissue Antigens 1997;50:355–358.

    Article  Google Scholar 

  19. Opelz G. Correlation of HLA matching with kidney graft survival in patients with or without cyclosporine treatment. Transplant. 1985;40:240–243.

    Article  CAS  Google Scholar 

  20. Hata Y, Ozawa M, Takemoto S, Cecka JM. HLA Matching. In: Terasaki PI, editor. Clinical Transpl. Los Angeles: UCLA Tissue Typing Laboratory; 1997. p. 381–396.

    Google Scholar 

  21. Terasaki PI, Cecka JM, Gjertson DW, Takemoto S. High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 1995;333(6):333–336.

    Article  PubMed  CAS  Google Scholar 

  22. Goes N, Urmson J, Ramassar V, Halloran PF. Ischemic acute tubular necrosis induces an extensive local cytokine response. Evidence for induction of interferon-gamma, transforming growth factor-beta 1, granulocyte-macrophage colony-stimulating factor, interleukin-2, and interleukin-10. Transplantation 1995;59(4):565–572.

    PubMed  CAS  Google Scholar 

  23. Takada M, Chandraker A, Nadeau KC, Sayegh MH, Tilney NL The role of the B7 costimulatory pathway in experimental cold ischemia/reperfusion injury. J Clin Invest 1997;100(5):1199–1203.

    Article  PubMed  CAS  Google Scholar 

  24. Tullius SG, Heemann U, Hancock WW, Azuma H, Tilney NL. Long-term kidney isografts develop functional and morphological changes which mimic those of chronic allograft dysfunction. Ann Surg 1994;220:425–432.

    Article  PubMed  CAS  Google Scholar 

  25. Troppmann C, Gillingham KJ, Benedetti E, Almond PS, Gruessner RW, Najarian JS, et al. Delayed graft function, acute rejection, and outcome after cadaver renal transplantation. The multivariate analysis. Transplantation 1995;59(7):962–968.

    Article  PubMed  CAS  Google Scholar 

  26. Alegre ML, Lenschow DJ, Bluestone JA. Immunomodulation of transplant rejection using monoclonal antibodies and soluble receptors. Dig Dis Sci 1995;40(1):58–64.

    Article  PubMed  CAS  Google Scholar 

  27. Attavar P, Budhai L, Kim BH, Roy-Chowdhury N, Roy-Chowdhury J, Davidson A. Mechanisms of intrathymic tolerance induction to isolated rat hepatocyte allografts. Hepatology 1997;26(5): 1287–1295.

    Article  PubMed  CAS  Google Scholar 

  28. Monaco AP, Wood ML. Studies on heterologous antilymphocyte serum in mice: Optimal cellular antigen for induction of immunological tolerance with ALS. Tran Proc 1970;2:489.

    CAS  Google Scholar 

  29. Sayegh MH, Turka LA. T cell costimulatory pathways: promising novel targets for immunosuppression and tolerance induction. J Am Soc Nephrol 1995;6(4):1143–1150.

    PubMed  CAS  Google Scholar 

  30. Denton MD, Reul RM, Dharnidharka VR, Fang JC, Ganz P, Briscoe DM. Central role for CD40/CD40L interactions in transplant rejection. Pediatric Nephrology 1998;2(1):6–15.

    CAS  Google Scholar 

  31. Kirk AD, Harlan DM, Armstrong NN, Davis TA, Dong Y, Gray GS, et al. CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997;94(16):8789–8794.

    Article  PubMed  CAS  Google Scholar 

  32. Sayegh MH, Fine NA, Smith JL, Rennke HG, Milford EL, Tilney NL. Immunologic tolerance to renal allografts after bone marrow transplants from the same donors [see comments]. Ann Intern Med 1991; 114(11):954–955.

    PubMed  CAS  Google Scholar 

  33. Spitzer TR, Delmonico F, Tolkoff-Rubin N, McAfee S, Sacktein R, Saidman S, et al. Combined HLA-matched donor bone marrow and renal transplantation for multiple myeloma with ESRD: induction of allograft tolerance through mixed lymphohematopoietic chimerism. Transplantation 1999;68:480.

    Article  PubMed  CAS  Google Scholar 

  34. Hricik DE, Almawi WY, Strom TB. Trends in the use of glucocorticoids in renal transplantation. Transplantation 1994;57(7):979–989.

    PubMed  CAS  Google Scholar 

  35. Ratcliffe PJ, Dudley CR, Higgins RM, Firth JD, Smith B, Morris PJ. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression. LancetLancet 1996;348(9028):643–648.

    Article  CAS  Google Scholar 

  36. Tran H, Acharya M, Auchincloss H, Carpenter CB, McKay D, Kirkman R, et al. Cyclosporine sparing effect of daclizumab in renal transplantation. J Am Soc Nephrol 1999;10:749.

    Google Scholar 

  37. Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group [see comments]. Transplantation 1999;67(7): 1036–1042.

    Article  PubMed  CAS  Google Scholar 

  38. Michael HJ, Francos GC, Burke JF, Besarab A, Moritz M, Gillum D, et al. Comparison of the effects of cyclosporine versus antilymphocyte globulin on delayed graft function in cadaver renal transplant recipients. Transplantation 1989;48:805.

    Article  PubMed  CAS  Google Scholar 

  39. Belitsky P, MacDonald AS, Cohen AD, Crocker J, Hirsch D, Jindal K, et al. Comparison of antilymphocyte globulin and continuous iv cyclosporine as induction immunosuppression for cadaver kidney transplants. Transplant Proc 1991;23:999.

    PubMed  CAS  Google Scholar 

  40. Gaston RS, Hudson SL, Deierhoi MH, Barber WH, Laskow DA, Julian BA, et al. Improved survival of primary cadaveric renal allografts in blacks compared with quadruple immunosuppression. Transplantation 1992;53:103.

    Article  PubMed  CAS  Google Scholar 

  41. Tesi RJ, Henry ML, Elkhammas EA, Ferguson RM. Predictors of long-term primary cadaveric renal transplant survival. Clin Transplants 1993;7:345.

    Google Scholar 

  42. Katznelson S, Cecka JM. Immunosuppressive regimens and their effect on renal allograft outcome. In: Terasaki PI, editor. Clin Transpl. Los Angeles: UCLA Tissue Typing Lab; 1997. p. 379–394.

    Google Scholar 

  43. Brennan DC, Flavin K, Lowell JA, Howard TK, Shenoy S, Burgess S, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999;67(7): 1011–1018.

    Article  PubMed  CAS  Google Scholar 

  44. Rubin RH, Tolkoff RN, Oliver D, Rota TR, Hamilton J, Betts RF, et al. Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation. Transplantation 1985;40(3):243–249.

    Article  PubMed  CAS  Google Scholar 

  45. Cockfield SM, Preiksaitis JK, Jewell LD, Parfrey NA. Post-transplant lymphoproliferative disorder in renal allograft recipients. Clinical experience and risk factor analysis in a single center. Transplantation 1993;56(1):88–96.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Jochen Klupp
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Randall E. Morris
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Harvard Medical School, Boston, MA, USA

    Mohamed H. Sayegh

  2. Mario Negri Institute for Pharmacological Research, Bergamo, Italy

    Giuseppe Remuzzi

Rights and permissions

Reprints and permissions

Copyright information

© 2001 Kluwer Academic Publishers

About this chapter

Cite this chapter

Klupp, J., Morris, R.E. (2001). New Agents on the Horizon. In: Sayegh, M.H., Remuzzi, G. (eds) Current and Future Immunosuppressive Therapies Following Transplantation. Springer, Dordrecht. https://doi.org/10.1007/978-94-010-1005-4_9

Download citation

  • DOI: https://doi.org/10.1007/978-94-010-1005-4_9

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-3876-8

  • Online ISBN: 978-94-010-1005-4

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation